hotspot -WSS

hotspot

author：comprehensive 2025-09-04 04:25:49 - browse：69

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The health care issue Democrats can’t solve: hospital reform

hotspot

WSS

What is microchimerism and how does it affect maternal health?

Humans aren't the only ones with an imagination. Rats have it too

Travis Kelce and the trap of celebrity vaccine endorsements

Medicare must police algorithms in Medicare Advantage, Dems say

Infant mortality in U.S. rose last year for first time in decades: CDC

How to convince healthy people to buy insurance

Wikipedia

hotspot

knowledge

Sports medicine is finally prioritizing gender equality

Will an HIV vaccine ever be a reality?

Sports medicine is finally prioritizing gender equality

What we owe ALS patients — and why one company fell short

Walensky prepares to leave CDC — and Congress — behind

Study points to new risk in gene therapy death of Terry Horgan

FDA approval of Sarepta Duchenne genetic therapy gives me hope

European officials brace for rough respiratory virus season

Malaria cases in Florida and Texas: Here’s what you need to know

After Sarepta trial failure, Duchenne families brace for more debate

knowledge

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Nobel honors Karikó and Weissman's enduring partnership

The stability of $0 premiums in Medicare Advantage

Health insurers' Q3 question: how much care are people getting?

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Wikipedia

explore

hotspot

knowledge